Portola Pharmaceuticals Enters Into Licensing Agreements

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 Million

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (NASDAQ: PTLA ), announced today that it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to Bristol-Myers Squibb Company and Pfizer Inc. to be developed as an antidote for apixaban and other Factor Xa inhibitors. Separately, Portola has entered into a clinical collaboration agreement with Bayer HealthCare to include its Factor Xa inhibitor rivaroxaban in this clinical development program in Japan.

Three oral Factor Xa inhibitors are currently on the market in Japan – Bristol-Myers Squibb and Pfizer’s apixaban, Bayer HealthCare’s rivaroxaban, and Daiichi Sankyo’s edoxaban – but an antidote is not yet approved. A universal antidote for Factor Xa inhibitors is needed for certain patients in Japan, as the clinical use of these novel oral anticoagulants is growing.

“These agreements allow Portola to expand the development and commercialization of andexanet alfa into Japan, which is a new country for us and the third largest market for Factor Xa inhibitors after the United States and EU 5 countries,” said William Lis, chief executive officer of Portola. “Bristol-Myers Squibb, Pfizer and Bayer all have extensive infrastructure and experience in Japan. With Bristol-Myers Squibb and Pfizer leading development and commercialization activities and Bayer providing support, the path forward for andexanet alfa as a Factor Xa inhibitor antidote in Japan will be accelerated.” 

Portola is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, for patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as in life-threatening or uncontrolled bleeding or for emergency surgery/urgent procedures. Portola retains full, worldwide commercial rights to andexanet alfa outside of Japan.

Bristol-Myers Squibb and Pfizer Agreement Details Under the terms of the agreement with Bristol-Myers Squibb and Pfizer, Portola will receive an upfront payment of $15 million and is eligible to receive potential regulatory and sales-based milestone payments totaling $90 million, as well as double-digit royalties based on andexanet alfa net sales in Japan. Bristol-Myers Squibb and Pfizer will be responsible for all development and regulatory activities for andexanet alfa in Japan and for commercializing the drug in Japan, assuming it receives regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW).

Portola previously entered into two separate non-exclusive clinical collaboration agreements with Bristol-Myers Squibb and Pfizer to support Phase 2 and Phase 3 development of andexanet alfa and apixaban in the United States and EU. Portola may receive additional milestone payments under these agreements based on developments in the United States and EU. Portola has completed a Biologics License Application (BLA) submission with the FDA and is awaiting acceptance for filing. The FDA assigned a PFUDA date of August 17, 2016, under an Accelerated Approval pathway. Portola plans to submit an EU application in 2017. Bristol- Myers Squibb and Pfizer continue to provide development and regulatory guidance to Portola for the andexanet alfa program in the United States and the EU.

Bayer Agreement Details Under the terms of the Bayer Clinical Collaboration agreement, Portola will receive an upfront payment of $5 million and is eligible to receive an additional milestone payment based on Japanese MHLW approval of andexanet alfa as an antidote for rivaroxaban. Bayer will provide technical support as well as fund clinical studies of andexanet alfa with rivaroxaban in Japan. Bayer will receive no commercial rights under this agreement.

Portola previously entered into two separate non-exclusive clinical collaboration agreements with Bayer HealthCare and its development partner, Janssen Pharmaceuticals, Inc. to support Phase 2 and Phase 3 studies of andexanet alfa and rivaroxaban in the United States and Europe. Portola may receive additional milestone payments under these agreements based on developments in the United States and EU. 

About the Need for a Factor Xa Inhibitor Antidote Commensurate with the increase in use of Factor Xa inhibitors, the number of hospital admissions due to bleeding associated with these agents continues to grow. Annually, 1 to 4 percent of patients treated with Factor Xa inhibitors may experience major bleeding, and an additional 1 percent may require emergency surgery. Currently, use of the Factor Xa inhibitor class in Japan is substantial and growing. Based on data from IMS Health, in the 12 months ending September 2015, sales of novel oral anticoagulants in Japan were more than $800 million. There is an unmet need for an antidote for some patients.

About Andexanet Alfa Andexanet alfa, an investigational drug, is a modified human Factor Xa molecule that acts as a decoy to target and sequester with high specificity both oral and injectable Factor Xa inhibitors in the blood. Once bound, the Factor Xa inhibitors are unable to bind to and inhibit native Factor Xa, thus allowing for the restoration of normal hemostatic processes. Andexanet alfa is the only compound being studied as an antidote for Factor Xa inhibitors that directly and specifically corrects anti-Factor Xa activity – the anticoagulant mechanism of these agents.

About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.

Portola Forward-looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: potential payments that may be received by Portola under these licensing agreements; the potential of these licensing arrangements to accelerate the development and commercialization of andexanet alfa in Japan; the potential of the availability of an antidote to affect prescribing behavior for Factor Xa inhibitors; continued receipt by Portola of development and regulatory support from our collaboration partners; increasing use of Factor Xa inhibitors and associated increase in patients requiring an antidote; andexanet alfa’s potential to treat patients needing reversal of Factor Xa anticoagulation effects, the projected number of patients that could benefit from andexanet alfa; the potential for andexanet alfa to become the first universal antidote for Factor Xa inhibitors; our plans for pursuit of regulatory approval of andexanet alfa, and the likelihood of clinical, regulatory and commercial success for andexanet alfa and our other product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: our expectation that we will incur losses for the foreseeable future and will need additional funds to finance our operations; we enter into collaborations that place certain aspects of the development of andexanet alfa out of our direct control; the pace of enrollment in our clinical trials; the results of our clinical trials related to the efficacy and safety of our product candidates; the risk that regulatory approval of our product candidates may not be received in a timely manner, or at all; our potential inability to manufacture andexanet alfa and our other product candidates on a commercial scale in a timely or cost-efficient manner; the accuracy of estimates regarding our expenses and capital requirements; our ability to successfully build a hospital-based sales force and commercial infrastructure; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates; and our ability to retain key scientific or management personnel. These and other risks and uncertainties are described more fully in our most recent filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, which was filed on March 2, 2015, and Quarterly Report on Form 10-Q for the third quarter of 2015, which was filed on November 9, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact: Ana Kapor Portola Pharmaceuticals ir@portola.com Media Contact: Julie Normart W2O Group jnormart@w2ogroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 118

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 261

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 276

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 235

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 258

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 176

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 47

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Cameco Prepares for Leadership Transition at Westinghouse Electric

Updated Category News Views 149

Cameco Acknowledges Leadership Changes at Westinghouse Cameco (TSX: CCO; NYSE: CCJ) has made a significant acknowledgment regarding the leadership transition at Westinghouse Electric Company. This moment marks a pivotal change as Patrick Fragman announces his decision to step down from his role as President and CEO of Westinghouse. Effective March 31, 2025, Patrick will...

Continue Reading
Discover Innovations at Taiwan Innotech Expo 2025 in AI

Updated Category News Views 296

Taiwan Innotech Expo 2025 Highlights The Taiwan Innotech Expo (TIE) is set to showcase the critical role of artificial intelligence (AI) in transforming various industries. Hosted in Taipei, this annual event brings together influential government agencies, including the Ministry of Economic Affairs and the National Science and Technology Council. The expo will open its...

Continue Reading
Explore Antarctica: A Unique Journey with Atlas Ocean Voyages

Updated Category News Views 225

Unveiling a Unique Antarctic Adventure Atlas Ocean Voyages, known for its intimate luxury expeditions, is set to elevate its offerings with a remarkable new program on board the luxury ship, World Traveller. This journey promises to provide guests not only breathtaking landscapes but also enriching experiences through collaboration with renowned photographer Karim Iliya...

Continue Reading
atNorth's Bold Expansion: Norway Meets Mega Data Site

Updated Category News Views 48

Setting the Stage in Haugaland Here's a bold move from atNorth that's got folks talking. This Nordic heavyweight isn't just dancing around the edges; they're making a big splash by staking their claim in Norway with a mega site that’s got ‘future’ written all over it. We’re talking a data center in Haugaland, starting with 120MW and aiming for a solid 350MW once...

Continue Reading
Volvo Group's CES Keynote: Paving the Path to Sustainability

Updated Category News Views 192

Volvo Group Spearheads Sustainability at CES At CES, the Consumer Electronics Show, Volvo Group’s President and CEO, Martin Lundstedt, captured the audience with a strong call to action regarding the future of transportation and infrastructure. Lundstedt emphasized the dire need for urgent changes in the industry to combat climate change, setting the tone for a vibrant...

Continue Reading